Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Scemblix® (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France

NCT06092879 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06092879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06092879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Scemblix® (Asciminib): Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML-CP in Real World Setting in France
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
March 6, 2024
Completion date
December 15, 2026
Enrollment
201 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia